Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus

European Journal of Clinical Pharmacology

Volumn 58, Issue 9, 2002, Pages 607-614

  Marques, Maria Paula ^a   Coelho, Eduardo Barbosa ^a   Dos Santos, Neife Aparecida Guinaim ^a   Geleilete, Tufik José Magalhães ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetes; Hypertension; Nisoldipine

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DIHYDROPYRIDINE DERIVATIVE; DRUG METABOLITE; LIDOCAINE; NISOLDIPINE; NORADRENALIN; PLACEBO; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; DIAGNOSTIC AGENT;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME ACTIVITY; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RANK SUM TEST; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TABLET; AREA UNDER THE CURVE; BLOOD; BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; HEART RATE; METABOLISM; MIDDLE AGED; STEREOISOMERISM;

ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEART RATE; HUMANS; HYPERTENSION; LIDOCAINE; MALE; MIDDLE AGED; NISOLDIPINE; NOREPINEPHRINE; STEREOISOMERISM;

EID: 0036460044     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0528-4     Document Type: Article

References (31)

1. Chandler MHH, Clifton GD, Lettieri JT, Mazzu AL, Allington DR, Thieneman AC, Foster TS, Harrison MR (1992) Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. J Clin Pharmacol 32:571-575
2. Heinig R, Adelmann HG, Ahr G (1999) The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. Eur J Clin Pharmacol 55:57-60
3. Radevski I, Skudicky D, Candy G, Sathekge S, Strugo V, Sareli P (1999) Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Am J Hypertens 12:194-203
4. Schaefer HG, Heinig R, Ahr G, Adelmann H, Tetzloff W, Kuhlmann J (1997) Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 51:473-480
5. van Harten J, Burggraaf J, Ligthart GJ, van Brummelen P, Breimer DD (1989) Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged, and the elderly. Clin Pharmacol Ther 45:600-607
6. Heinig R, Muschalek V, Ahr G (1994) Determination of the enantiomers of nisoldipine in human plasma using high-performance liquid chromatography on a chiral stationary phase and gas chromatography with mass-selective detection. J Chromatogr B 655:286-292
7. Tokuma Y, Noguchi H (1995) Stereoselective pharmacokinetics of dihydropyridine calcium antagonists. J Chromatogr A 694:181-193
8. Frost N, Ahr G, Weber H, Wingender W, Kuhlmann J (1990) Nisoldipine enantiomers - Assessment of pharmacokinetics by stable isotope technique. In: Kuhimann J, Wingender W (eds) Dose-response Relationship of Drugs. W Zuckschwerdt Verlag München, Munich, pp 87-92
9. Plosker GL, Faulds D (1996) Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension. Drugs 52:232-253
10. Zannad F (1995) Clinical pharmacology of nisoldipine coat core. Am J Cardiol 75:41E-45E
11. Heinig R (1998) Clinical pharmacokinetics of nisoldipine coat-core. Clin Pharmacokinet 35:191-208
12. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Bäärnhielm C, Berntsson P (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 34:1838-1844
13. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T (2000) Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 55:843-852
14. Kivistö KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S-48S
15. Wildt SN, Kearns GL, Leeder JS, Van den Anker JN (1999) Cytochrome P450 3A. Ontogeny and drug disposition. Clin Pharmacokinet 37:485-505
16. Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT (2000) Involvement of CYP1A2 and CYP3A4 in lidocaine n-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 28:959-965
17. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 46:521-527
18. Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT (1998) Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 54:561-565
19. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y (1997) Prediction on in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171
20. Muñoz AE, Miguez C, Rubio M, Bartellini M, Levi D, Podestá A, Niselman V, Terg R (1999) Lidocaine and mono-ethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration. Dig Dis Sci 44:789-795
21. Laroche N, Leneveu A, Roux A, Flouvat B (1998) Capillary gas chromatographic method for the measurement of small concentrations of monoethylglycinexylidide and lidocaine in plasma. J Chromatogr B 716:375-381
22. Schütz E, Shipkova M, Niedmann PD, Wieland E, Armstrong VW, Oellerich M (1998) Determination of mono-ethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: Modified precipitation procedure and HPLC compared. Clin Chem 44:1269-1274
23. American Diabetes Association (2002) Treatment of hypertension in adults with diabetes. Diabetes Care 25:S71-S73
24. Shaw MA (2001) New insights into drug metabolism and toxicology. Report of a symposium on drug metabolism and toxicity held at the British Pharmacological Society Meeting in Cardiff, UK, July 2000. Br J Clin Pharmacol 51:209-212
25. Schenkman JB (1991) Induction of diabetes and evaluation of diabetic state on P450 expression. Methods Enzymol 206:325-331
26. Iber H, Li-Masters T, Chen Q, Yu S, Morgan ET (2001) Regulation of hepatic cytochrome P450 2C11 via cAMP: Implications for down-regulation in diabetes, fasting, and inflammation. J Pharmacol Exp Ther 297:174-180
27. Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW (2000) Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182-190
28. Hannon-Fletcher MPA, O'Kane MJ, Moles KW, Barnett YA, Barnett CR (2001) Lymphocyte cytochrome P450-CYP2E1 expression in human IDDM subjects. Food Chem Toxicol 39:125-132
29. Shiffman ML, Luketic VA, Sanyal AJ, Thompson EB (1996) Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease. Ther Drug Monit 18:372-377
30. Marques MP, Santos NAG, Coelho EB, Bonato PS, Lanchote VL (2001) Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: Applications to pharmacokinetics. J Chromatogr B 762:87-95
31. Forster CD, Macdonald IA (1999) The assay of the catechol-amine content of small volumes of human plasma. Biomed Chromatogr 13:209-215